Efficacy Study of ABR-215050 to Treat Prostate Cancer

NCT00560482 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: ABR-215050, tasquinimod
DRUG: Placebo

Sponsor

Active Biotech AB